Today: Today: Boston Scientific Corp. (BSX) Stake Maintained by Amica Mutual Insurance Co.

Today: Boston Scientific Corp. (BSX) Stake Maintained by Amica Mutual Insurance Co.

Amica Mutual Insurance Co. continued to hold its position in Boston Scientific Corp. (NYSE:BSX) during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 96,465 shares of the company’s stock at the end of the third quarter. Amica Mutual Insurance Co.’s holdings in Boston Scientific Corp. were worth $2,296,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of BSX. Trust Co. of Vermont increased its position in shares of Boston Scientific Corp. by 2,298.3% in the third quarter. Trust Co. of Vermont now owns 4,221 shares of the company’s stock valued at $100,000 after buying an additional 4,045 shares during the period. Synovus Financial Corp acquired a new position in shares of Boston Scientific Corp. during the third quarter valued at $102,000. Quadrant Capital Group LLC increased its position in shares of Boston Scientific Corp. by 1.7% in the second quarter. Quadrant Capital Group LLC now owns 4,844 shares of the company’s stock valued at $105,000 after buying an additional 83 shares during the period. Bronfman E.L. Rothschild L.P. increased its position in shares of Boston Scientific Corp. by 1.5% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 4,511 shares of the company’s stock valued at $107,000 after buying an additional 66 shares during the period. Finally, Global X Management Co. LLC increased its position in shares of Boston Scientific Corp. by 91.8% in the second quarter. Global X Management Co. LLC now owns 4,683 shares of the company’s stock valued at $109,000 after buying an additional 2,242 shares during the period. Hedge funds and other institutional investors own 89.96% of the company’s stock.

Shares of Boston Scientific Corp. (NYSE:BSX) traded down 0.99% during mid-day trading on Monday, hitting $20.94. The company had a trading volume of 1,054,375 shares. The company has a market cap of $28.51 billion, a PE ratio of 395.09 and a beta of 1.15. The firm has a 50-day moving average of $22.11 and a 200-day moving average of $23.08. Boston Scientific Corp. has a 12 month low of $15.67 and a 12 month high of $24.79.

Boston Scientific Corp. (NYSE:BSX) last posted its earnings results on Wednesday, October 26th. The company reported $0.27 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. The company had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.07 billion. Boston Scientific Corp. had a return on equity of 23.25% and a net margin of 0.99%. Boston Scientific Corp.’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.24 earnings per share. On average, analysts expect that Boston Scientific Corp. will post $1.10 EPS for the current year.

BSX has been the topic of several research reports. TheStreet upgraded shares of Boston Scientific Corp. from a “hold” rating to a “buy” rating in a report on Wednesday, October 26th. Zacks Investment Research cut shares of Boston Scientific Corp. from a “buy” rating to a “hold” rating in a research note on Monday, October 31st. Citigroup Inc. raised their price objective on shares of Boston Scientific Corp. from $28.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, October 6th. Evercore ISI reaffirmed a “buy” rating and set a $26.00 price objective (up previously from $25.50) on shares of Boston Scientific Corp. in a research note on Sunday, July 31st. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Boston Scientific Corp. in a research note on Friday, October 14th. Five investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $25.70.

Boston Scientific Corp. Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

Related posts

Leave a Comment